INTRODUCTION
Genomic and proteomic studies have established that cancer is a systems biology disease that involves a large number of genes spanning multiple signaling pathways as shown in lung, 1 pancreatic, 2 breast, 3 brain 4 and colorectal 5 cancers. In the case of lung cancer, hundreds of genetic alterations spanning 18 signaling pathways have been found. 1, 6 The large number of mutations make it a significant challenge to identify effective treatments for this disease. According to the American Cancer Society, the disease has taken 160,340 lives in the U.S in 2011 alone. Non-small cell lung cancer (NSCLC) is the most prevalent form of the disease (85 percent of all cases). It is characterized by poor prognosis and aggressive behavior. First-line treatment options for the majority of patients include chemotherapeutics that cause significant side effects. New treatments with lower toxicity and greater efficacy are urgently needed.
Studies have shown that approved and experimental drugs as well as chemical probes bind and modulate the function of multiple proteins. 7, 8 This property, also known as polypharmacology, offers an opportunity to uncover new targets. Recently, we have explored the possibility of using structure-based docking to generate a protein-compound interactome that can be used as a hypothesis generation tool to uncover new targets for small molecules.
We docked more than 1,200 compounds to more than 3,000 pockets from 1,000 proteins. The resulting structural protein-ligand interactome (SPLINTER) is available at http://www.biodrugscreen.org 9 .
The scoring of protein-compound interactions in this interactome enables the rank-ordering of compounds for individual targets for purposes of hit identification, but also makes it possible to rank-order proteins for a list of potential targets for a compound or drug of interest. In a recent application, we used the interactome to search for compounds that mimicked the binding profile of an existing drug. 10 We stipulated that such compounds may exhibit similar pharmacokinetic properties and efficacy to the drug and possibly serve as leads for the development of cancer therapeutics. From this study, several compounds were uncovered with potent anti-cancer properties and in vitro studies suggested suitable pharmacokinetic (PK) properties. 10 Here, we extend SPLINTER by docking more than 1,000 FDA-approved drugs to targets in the interactome. The cancer drug erlotinib was used as a template to search for other approved drugs that may possess similar anti-cancer properties. Erlotinib is used in the treatment of nonsmall cell lung cancer (NSCLC) patients. Twelve drugs are tested for their effect on cell growth in a panel of NSCLC cells. We mined patient records to study the potential association between drug exposure and lung cancer occurrence in patients taking these drugs. 11 In vivo preclinical studies using human NSCLC xenografts in NOD-SCID mice were carried out to probe these drugs for their effect in lung cancer.
RESULTS AND DISCUSSION
Docking approved drugs to the human structural proteome. The solventaccessible surface area (SASA) and volume were determined for each pocket to provide insight into their physico-chemical properties (Fig. 1) Fig. 1C and 1I ). The mean number of donors was 17.3 and 14.6 for cancer non-cancer targets ( Fig. 1F and 1L ).
Physico-chemical properties and polypharmacology. Flexibility and solubility are investigated for approved drugs, approved cancer drugs, and publicly-available NCI compounds. Flexibility is represented by the number of rotatable bonds. Using a threshold value of 0.1 µM, the number of targets for all three classes versus the size of the small molecule is provided in Fig. 2A . The most promiscuous compounds have about 5 rotatable bonds. The most selective compounds had less than 3 rotatable bonds. High promiscuity is predicted even for compounds with more than 10 rotatable bonds (Fig. 2B) . In fact, some drugs with 20 rotatable bonds had more than 1,000 predicted targets at the 0.1 µM threshold. Approved cancer drugs followed a similar pattern. Rotatable bonds for NCI compounds, non-cancer drugs and cancer drugs showed different distributions (Fig. 2B) . A significantly greater fraction of NCI compounds had 3-5 rotatable bonds compared with drugs and non-cancer drugs. Rotatable bonds were more uniformly distributed among approved drugs. A significant fraction of drugs and approved drugs had more than 7 rotatable bonds in significant contrast to NCI compounds.
Cancer drugs were even more likely to have more than 7 rotatable bond than non-cancer drugs.
It has been suggested that hydrophobic compounds are more promiscuous. 13 Lipophilicity is quantified by the partition coefficient that corresponds to the ratio of the concentration of compound in water versus n-octanol. Several algorithms have been developed to predict the logarithm of the partition coefficient (cLogP). 14 A plot of the number of pockets versus cLogP for all three classes of compounds shows a gradual increase in promiscuity for compounds with increasing cLogP (Fig. 2C ). This is observed for approved non-cancer drugs, approved cancer drugs, and NCI compounds. The mean cLogP was 2.3, 2.7 and 2.5 for the three classes of compounds, suggesting that cancer drugs had slightly more hydrophobic character than other drugs and compounds. This is illustrated by the distribution in Fig. 2D Fig. S1 . It was notable that the overwhelming majority of these drugs were fragment-like with molecular weights below 300 Da. They consisted of a single heterocyclic or aromatic ring structure with various appendages. This suggests that smaller compounds may be the most effective approach to achieve selective polypharmacology.
A measure of the predicted polypharmacology of compounds was defined using the ratio of targets defined by the number of proteins that exceeded the 0.1 µM threshold to the number of proteins below this threshold. The distribution of this ratio is shown in Fig. 2F . The majority of NCI compounds and drugs exhibit a ratio below 0.2, with compounds showing greater selectivity than drugs. Cancer drugs exhibit less selectivity than NCI compounds and noncancer drugs (Fig. 2F) .
A survey of the literature reveals that at least four of these drugs bind to targets that have previously been implicated in cancer. For example, isoetharine and salbutamol are adrenergic β1, β2 agonists and are used for the treatment of bronchospasm, asthma, and chronic obstructive pulmonary disease. They bind and activate the β1 and β2 adrenergic receptors, which are involved in multiple metabolism pathways including calcium signaling, gap junction, salivary secretion, and endocytosis. 17 Recent studies suggest these receptors are critical for the development of colorectal cancer. 18 The third drug is methyprylon, a sedative of the piperidinedione derivative family and a treatment for insomnia. Up-regulation of microRNA miR-155 inhibits γ-aminobutyric acid A receptor 1 (GABRA1, target of methyprylon) and promotes tumor growth. 19 The targets of the fourth drug (bromfenac) are cox1 and cox2, which are well-known to be involved in inflammation, which in turn has been implicated in cancer.
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Drug-target network. The interaction between small molecules and their targets can be understood within the context of a drug-target network. 8, 21 The availability of complete proteindrug or protein-compound interactome affords the construction of a complete drug-target network ( Fig. 3) . In this network, a node represents a molecule and two nodes are linked if they share a cancer target. A protein is considered a target to a small molecule if its ChemScore predicted affinity is higher than 0.01 µM. We constructed a drug network for cancer and noncancer FDA-approved drugs (Fig. 3A) .
A comparison of the two networks reveals a total of 120,314 and 54,632 edges, with 559
and 402 nodes for the NCI compounds and FDA-approved drugs, respectively. To gain insight into the level of interconnections of the nodes, we computed the mean degree for each network (the degree of a node corresponds to the number of edges connected to the node). The NCI compound network exhibited a mean degree of 430, while the FDA-approved drug network showed a mean degree of 272. The number of non-redundant shortest pathways going through each node (betweenness) was also computed for each network. The mean betweenness for the NCI network was 128 while that of the FDA-approved drug network was 131. A plot of the degree versus betweenness is shown in Fig. 3B . The top 10 drugs with highest betweenness and degree are provided in Table 2 . It is worth noting that two of the ten compounds are cancer drugs, and one, namely bexarotene, is used in the treatment of lung cancer (Table 2) . 22 Finally, the mean clustering coefficient was determined to gain insight into the topology of the networks.
Clustering coefficient of the NCI compound network is 0.913 while that of the FDA-approved drug network is 0.898. It was found that the NCI compound network was slightly less loosely connected than the FDA-approved drug network. These values are in excellent agreement with a previous study that computed them from a drug-network based on experimental data.
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A search for new cancer drugs using compound polypharmacology. Previously, we had used predicted off-targets of erlotinib to identify compounds that mimicked the pharmacokinetic and anti-cancer properties of the cancer drug. Here, we extend this concept to identify FDA-approved drugs that could be potentially used in the treatment of lung cancer.
Following the same approach a fingerprint is defined based on erlotinib's predicted off-targets. 10 We selected the top 12 drugs with highest similarity to the binding profile of erlotinib as measured by a Tanimoto coefficient that was determined by comparing fingerprints ( In an effort to assess the effect of each drug on cancer cell growth, we performed an MTT study for each drug in three NSCLC cancer cell lines, namely H1299, A459, H460, and one non-cancer WI38 fibroblast cell line. All 32 MTT curves are provided in the Supporting
Information Fig. S1 to S4. EC 50 that were obtained from these curves are provided in Table 4 .
The most cytotoxic drug was podophyillotoxin with EC 50 in the nanomolar concentrations (Table   4 ). This was not a surprising finding since this drug is a derivative of etoposide a well-known chemotherapeutic. The second most potent drug was dasatinib. In A549 and WI38, the compound inhibited proliferation at sub-micromolar EC 50 . Astemizole was the next most cytotoxic drug, EC 50 of 12, 9, 10, and 8 µM for H1299, H460, A549 and WI38 cells, respectively.
Lapatinib, another kinase inhibitor, showed significantly less inhibition of cell proliferation in all three cell lines with EC 50 values between 30 to 40 µM. Bexarotene, which was previously tested in lung cancer clinical trials revealed weaker anti-proliferative effect (EC 50 = ~50 µM), showed weaker effect on WI38 proliferation. Ergotamine, an analog of dihydroergotamine, had higher potency with an EC 50 ~ 25 µM in H1299 and H460, and even greater potency in A549 cells (13 µM). What sets this compound apart from the others is that it had significantly less effect on WI38, providing a potential therapeutic window. Losartan, a drug used mainly to treat high blood pressure, showed very little cytotoxicity even at concentrations up to 100 µM.
Mining and statistical analysis of clinical drug exposure and disease occurrence.
Patient cohorts were defined based on different drugs. For losartan, patient cohort was constructed as co-occurrence of hypertension prior to lung cancer plus mono-occurrence of hypertension without any kind of cancer. For ergotamine, patient cohort was constructed as cooccurrence of migraine pain prior to 12 major types of cancer (Supporting Information Table S1) plus mono-occurrence of migraine pain without any kind of cancer. All cohorts contained patients who had first diagnosis of hypertension or migraine pain at 30 years of age or older. We extracted 67,109 patients in the losartan/hypertension cohort, among which 65,411 patients had not been exposed to losartan and 1,698 patients had been exposed to losartan before first diagnosis of lung cancer or last visit date; and among which 1,574 patients were diagnosed with lung cancer sometime after first hypertension diagnosis and 65,535 patients were not diagnosed with any cancer before last visit date (Table 5 ). For ergotamine/migraine pain cohort, we extracted 44,721 patients in the ergotamine/migraine pain cohort, among which 44,509 patients had not been to ergotamine and 212 patients had been treated with ergotamine before first diagnosis of any of major cancer types; and among which 1,171 patients were diagnosed with any of 12 major cancers after first migraine pain diagnosis and 43,550 patients were not diagnosed with any cancer before last visit date (Table 6 ).
Survival statistical analysis was conducted for the association of drug exposure and risk of cancer (Fig. 4) . Time to occurrence of cancer by drug exposure status was analyzed using 
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In vivo studies in mouse xenograft models. Astemizole, losartan, and ergotamine were evaluated for their effect in vivo on tumor growth using an H460 NSCLC human xenograft model. Two studies were carried out. The first study was done by orally dosing mice with ergotamine at 50 mg/kg orally (n = 7) (Fig. 5A ). Vehicle mice (n = 8) were dosed with the methylcellulose. The study was terminated at day 21. While differences in tumor volume in vehicle versus compound-treated mice were not statistically significant, there were some trends worth noting in this early exploratory study. At day 15, tumor volume ranged from 249 to 944 mm 3 for ergotamine-treated mice, and 274 to 743 mm 3 for vehicle.
Another study was carried out with losartan and astemizole. These drugs were administered i.p. at a dose of 50 and 10 mg/kg daily, respectively (n = 10 for losartan and vehicle; n = 9 for astemizole). Another difference is that mice were dosed with drug for a period of 7 days before tumors were implanted. At day 24, tumor size was measured (Fig. 5B) . Tumor volume ranged from 1,770 to 4,600 mm 3 for vehicle mice. For treated mice, tumor size ranged from 1271 to 3,773 for losartan, and 1,470 to 3,969 mm 3 for astemizole, respectively. The median tumor volume was 2,800, 2,463, and 2,810 for vehicle, losartan, and astemizole, respectively. Tumor weights, which measured on the last day of the study were 50 percent smaller for losartan-treated mice (p<0.01), and 15 percent for mice treated with astemizole (p<0.01) (Fig. 5C) . Four of the losartan-treated mice developed tumors that weight less than 2.5 g, compared with none of the vehicle (smallest tumors for vehicle was 3.2 g). Three astemizole treated mice developed tumors that weighed less than 3.2 g. During this study, the animal's body weight was monitored (Supporting Information Fig S5) and no significant alteration was found.
Histopathology studies were performed on the resected lung tumors to evaluate the cell cycle arrest of NSCLC cells. The mitotic index (MI) was measured, which is defined as the ratio of mitotic cell to non-mitotic cells for tumor tissues treated with vehicle, losartan, and astemizole.
The results were 7, 18, and 8 respectively. These data seem to suggest that losartan has a significant propensity to cause G 2 M arrest in the cell cycle, which may lead to apoptosis, similar to mechanism of Paclitaxel, a microtubule stabilizer and a well-known cancer drug.
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CONCLUSION
We extend our protein-compound interactome SPLINTER by docking FDA-approved drugs to a large set of proteins within the dataset. The scoring of these protein-compound structures using
ChemScore led to a predicted binding affinity for each protein-compound pair. The resulting matrix of predicted binding affinities can be used to rank proteins for each drug to identify the most likely targets for that drug, or to rank drugs for individual proteins to identify potential hit compounds. A protein is defined as a target for a drug if its predicted binding affinity exceeds a pre-defined threshold value. This matrix was instrumental to enable us to get deeper insight into the pharmacology of these drugs particularly in cancer. Since our interactome consists of cancer and non-cancer proteins, it was possible to identify drugs that exhibited greater selectivity to cancer targets. The data revealed that selectivity for cancer targets can only be achieved only for compounds with fewer predicted targets overall. In addition, it was possible to study the predicted polypharmacology of compounds and drugs. In general compounds from chemical libraries had greater promiscuity than drugs, but cancer drugs exhibited more promiscuity than non-cancer drugs. In addition, physico-chemical properties of compounds and drugs led to significant differences predicted polypharmacology. The data also revealed that smaller fragment-like compounds exhibited greater selectivity. Finally, protein-compound scores enabled a network analysis and led to the discovery of highly interconnected hubs that may yield new cancer therapeutics among existing FDA-approved drugs. Interestingly, the parameters of these networks based on predicted binding affinity were in good agreement with previous network constructed on experimentally-determined interactions.
Beyond a deeper understanding of compound pharmacology, the protein-compound score matrix provided an opportunity to extend on previous work that revealed that binding profiles can be used effectively to identify compounds that share similar pharmacology. 28 The binding profile of compounds was encapsulated into a fingerprint. We defined these fingerprints as bits of 0 and 1 that correspond to whether the compounds exceeded a pre-defined threshold. In our previous application we used a drug to search commercial libraries for compounds that mimic the properties of that drug. 28 Here, we extend this approach to FDA-approved drugs that we have docked to all proteins within our interactome. As we have done previously, we use the lung cancer drug erlotinib as a template and use its fingerprint to search for other approved drugs that share a similar fingerprint with the expectation that these drugs will possess similar pharmacology to erlotinib. The fingerprints are compared using a Tanimoto coefficient as we have done previously. 28 From this analysis, the top 12 drugs that possessed the most similar fingerprints as erlotinib were further analyzed. It was interesting that three of these drugs are already in use for treatment of lung and other cancers. Among the remaining nine drugs, cellular studies revealed that except for one case, these drugs were micromolar inhibitors of NSCLC proliferation in a panel of NSCLC that include A549, H1299 and H460.
We selected two drugs (losartan and ergotamine) that are commonly prescribed in the clinic and for which there is extensive clinical data at the Regenstrief Institute database. We were interested in evaluating whether patients that take these drugs are less likely to develop cancer than those that do not. Mining patient records at the Regenstrief Institute, our preliminary results indicate that ergotamine may hasten the onset of cancer; while losartan had the opposite effect. Further statistical analyses and controls are needed in future studies to make a definite link between these drugs and lung cancer in patients. Three drugs were tested in a subcutaneous model of NSCLC in NOD-SCID mice. Mice treated with losartan and astemizole had tumors that weighed 50% and 15% less than vehicle, respectively. In histopathological analysis of resected lung tumors, losartan induced more significant G 2 M arrest in the cell cycle.
MATERIALS AND METHODS
Docking approved drugs structures. Previously, we had docked 1592 compounds from the NCI diversity set to 1918 binding pockets that were found at the surface of protein structures that have been previously implicated in cancer. 9, 10 In this work, an additional 1084
FDA-approved small molecule drugs obtained from DrugBank 29 were docked to 2546 cavities on 1738 proteins following the same process that we described previously. 9 The strength of the interaction between drug and target was determined using the ChemScore empirical scoring function. 
Calculation
